Real-world evidence on all-oral, interferon-free regimens with Ombitasvir/Paritaprevir/r and Dasabuvir for treatment of chronic HCV patients receiving opioid substitution therapy in the German Hepatitis C-Registry

Background: Chronic hepatitis C virus (HCV) infection is highly prevalent in patients with a history of intravenous drug abuse; however historically, implementation of HCV treatment in this patient group in real-world remained challenging. With all-oral, interferon-free HCV regimens available and the favorable setting of opiate substitution treatment (OST), conditions are now potentially more adequate for successful HCV treatment in these patients. In clinical trials with OST patients with chronic HCV genotype 1 (GT1) infection, the regimen of ombitasvir (OBV), paritaprevir (co-dosed with ritonavir [PTV/r]) with dasabuvir (DSV) and/or ribavirin (RBV) achieved a sustained virological response (SVR) rate of 96.4%. However, real-world data on this regimen in this group is currently limited.